Search Within

Martin Stuart Tallman

  1. "2017"
Formats
  1. Meeting Abstract (34)
  2. Journal Article (27)
Groups
  1. Adult Leukemia (61)
  2. Center for Hematologic Malignancies (61)
  3. Department of Medicine (61)
  4. Hematologic Malignancies, Division of (61)
  5. Executive Committee, Center for Hematologic Malignancies (15)
  6. GSK Faculty (15)

More Groups

People
  1. Eytan Stein (16)
  2. Ross Levine (12)
  3. Sean Devlin (8)
  4. Jae Park (6)
  5. Bartlomiej Getta (4)
  6. Yanming Zhang (4)

More People

Years
  1. 2017 (61)
Publications
  1. Blood (32)
  2. Journal of Clinical Oncology (5)
  3. Biology of Blood and Marrow Transplantation (4)
  4. Annals of Hematology (3)
  5. Leukemia (3)
  6. Haematologica (2)

More Publications

Publishers
  1. American Society of Hematology (32)
  2. American Society of Clinical Oncology (5)
  3. Nature Publishing Group (5)
  4. Elsevier Inc. (4)
  5. Springer (3)
  6. Elsevier Ltd (2)

More Publishers

Results (61)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment patterns and characteristics of acute promyelocytic leukemia (APL) patients receiving arsenic trioxide (ATO) therapy in a real-world setting
    Meeting Abstract

    Tang, B.; Gabriel, S.; Zhou, J.; Pathak, A. K.; Irwin, D.; Riehle, E.; Lo-Coco, F.; Tallman, M. S.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study
    Meeting Abstract

    Stein, E. M.; Dinardo, C. D.; Pollyea, D. A.; Fathi, A. T.; Roboz, G. J.; Altman, J. K.; Stone, R. M.; Flinn, I.; Kantarjian, H. M.; Collins, R.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML
    Meeting Abstract

    Stone, R. M.; Collins, R.; Tallman, M. S.; Walter, R. B.; Karanes, C.; Patel, P. A.; Vusirikala, M.; Coombs, C. C.; Olson, G.; Jain, V. K.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
    Meeting Abstract

    Ruppert, A. S.; Byrd, J. C.; Heerema, N. A.; Smith, M. R.; Godwin, J. E.; Couban, S.; Fehniger, T. A.; Thirman, M.; Halvorson, A. E.; Tallman, M. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia
    Journal Article

    Liu, H. D.; Ahn, K. W.; Hu, Z. H.; Hamadani, M.; Nishihori, T.; Wirk, B.; Beitinjaneh, A.; Rizzieri, D.; Grunwald, M. R.; Sabloff, M.; more...
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults
    Journal Article

    Litzow, M. R.; Fielding, A. K.; Luger, S. M.; Paietta, E.; Ofran, Y.; Rowe, J. M.; Goldstone, A. H.; Tallman, M. S.; Lazarus, H. M.
    Bone Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • Graft-vs-leukemia effect in acute lymphoblastic leukemia: Mild acute graft-vs-host disease protects against relapse and improves survival after allogeneic transplantation: A CIBMTR analysis
    Meeting Abstract

    Yeshurun, M.; Weisdorf, D. J.; Zhang, M. J.; Wang, H. L.; Flowers, M. E.; De Lima, M.; Rowe, J. M.; Sandmaier, B. M.; Tallman, M. S.; Verneris, M. R.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Association between Nuclear SET domain (NSD) Protein Lysine Methyltransferases (KMT) expression and poor prognosis in acute promyelocytic leukemia (APL) patients treated with ATRA and anthracycline protocol
    Meeting Abstract

    Wagatsuma, V. M. D. D.; Pereira-Martins, D. A.; Mendoza, S. E. S.; Koury, L. C. A.; Nascimento, M. C.; Melo, R. A. M.; Bittencourt, R.; Pagnano, K. B.; Pasquini, R.; Chiattone, C.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Low relapse rate in younger patients ≤ 60 years old with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) treated with crenolanib and cytarabine/anthracycline chemotherapy
    Meeting Abstract

    Wang, E. S.; Tallman, M. S.; Stone, R. M.; Walter, R. B.; Karanes, C.; Jain, V.; Collins, R. H.
    Blood (2017)

    Fulltext@MSK | Save
  • Genetic profiling and deep IDH1 mutation clearance to ≤0.04% in ivosidenib (AG-120)-treated patients with mutant IDH1 relapsed or refractory and untreated AML
    Meeting Abstract

    Stone, R. M.; Choe, S.; Zhang, V.; Marteyn, B.; Penard-Lacronique, V.; Wang, H.; DiNardo, C. D.; Stein, E. M.; Fathi, A. T.; Tallman, M. S.; more...
    Blood (2017)

    Fulltext@MSK | Save